NCT04678921
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment of C5aR inhibitors, T-cell, or NK-cell therapy; Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT04678921